1.89
Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten
Is Acumen Pharmaceuticals Inc. stock a dividend growth opportunityJuly 2025 Macro Moves & Real-Time Buy Zone Alerts - Newser
Can Acumen Pharmaceuticals Inc. stock hit analyst price targetsJuly 2025 WrapUp & AI Powered Buy/Sell Recommendations - Newser
Acumen presents new research on Alzheimer’s treatment delivery By Investing.com - Investing.com Canada
Acumen Pharmaceuticals (ABOS) Stock Analysis Report | Financials & Insights - Benzinga
Acumen Pharmaceuticals Presents Results on Alzheimer’s Disease at Conference - Yahoo
Acumen and JCR Advance Next-Generation CNS Therapeutics with EBD™ Technology - citybiz
What analysts say about Acumen Pharmaceuticals Inc stockStock Liquidity Analysis & Invest Like A Pro - earlytimes.in
Acumen Pharmaceuticals highlights enhanced brain delivery technology for oligomer-selective antibodies - marketscreener.com
Acumen (NASDAQ: ABOS) reports CTAD results on 15 to 68-fold delivery and ALTITUDE-AD recruitment - Stock Titan
Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Wall Street analysts’ outlook for Acumen Pharmaceuticals Inc (ABOS) - Setenews
Is Acumen Pharmaceuticals Inc. stock supported by innovation pipeline2025 Breakouts & Breakdowns & Consistent Growth Equity Picks - moha.gov.vn
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $6.75 Average Target Price from Analysts - Defense World
Is Acumen Pharmaceuticals Inc a good long term investmentTrade Execution Strategies & Big Profit Small Investment - earlytimes.in
Published on: 2025-11-21 08:02:34 - newser.com
Will Acumen Pharmaceuticals Inc. stock go up soonTrade Risk Assessment & Capital Efficiency Focused Ideas - newser.com
Why Acumen Pharmaceuticals Inc. stock is favored by top institutionsWeekly Trade Summary & Free AI Powered Buy and Sell Recommendations - newser.com
Using data models to predict Acumen Pharmaceuticals Inc. stock movementQuarterly Profit Report & Expert Approved Momentum Ideas - newser.com
How risky is Acumen Pharmaceuticals Inc. stock nowJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - newser.com
Is Acumen Pharmaceuticals Inc. stock dividend yield sustainableQuarterly Profit Summary & Verified Entry Point Signals - newser.com
Acumen Pharmaceuticals (ABOS) Price Target Decreased by 20.59% to 6.88 - MSN
Can Acumen Pharmaceuticals Inc. rally from current levelsTrade Performance Summary & Fast Exit and Entry Strategy Plans - newser.com
Is Acumen Pharmaceuticals Inc. stock recession proofJuly 2025 Retail & Daily Oversold Bounce Ideas - newser.com
Reversal indicators forming on Acumen Pharmaceuticals Inc. stockJuly 2025 News Drivers & Entry and Exit Point Strategies - newser.com
Is Acumen Pharmaceuticals Inc. stock attractive for passive investorsQuarterly Trade Summary & Daily Technical Stock Forecast Reports - newser.com
B of A Securities Maintains Acumen Pharmaceuticals (ABOS) Buy Recommendation - Nasdaq
ABOS: B of A Securities Lowers Price Target But Maintains Buy Ra - GuruFocus
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - The Manila Times
SR Bancorp (NASDAQ: SRBK) announces $0.05 dividend payable Oct. 15 - Stock Titan
Acumen Pharmaceuticals begins open-label extension for Alzheimer’s drug By Investing.com - Investing.com Canada
How to forecast Acumen Pharmaceuticals Inc. trends using time seriesJuly 2025 Breakouts & Reliable Volume Spike Alerts - newser.com
Acumen stock maintains Buy rating at Stifel ahead of late-2026 readout - Investing.com UK
Acumen Pharmaceuticals Reports Q3 2025 Financial Results - MSN
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease - The Manila Times
Acumen Pharmaceuticals begins open-label extension for Alzheimer’s drug - Investing.com India
Acumen Pharmaceuticals (NASDAQ: ABOS) doses first patient in Phase 2, 52-week OLE - Stock Titan
Will a bounce in Acumen Pharmaceuticals Inc. offer an exitJobs Report & Expert Curated Trade Setups - newser.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):